Skip to main content
. 2020 May 14;40(11):e00663-19. doi: 10.1128/MCB.00663-19

TABLE 2.

Summary of cell lines and treatments used in this study

Cell line(s) Description (reference or source) Treatment(s) Expt(s)
MDCK (hTWIST1 O/E) MDCK cells stably overexpressing hTWIST1 (54) Transfection with pCMV-XX-HA constructs for partners IP MS, co-IP validation
C3H10T1/2 Mesenchymal stem cells (ATCC) Transfection with BiFC constructs BiFC, scratch assay
mESC EB formation and doxycycline induction qPCR analysis or RNA-seq
    A2loxcre 41
 Twist1−/− and Twist1+/− Derived from A2loxcre by CRISPR editing
    T0, TT, T3, T4, and T12 Derived from A2loxcre by induced cassette exchange; doxycycline inducible